Value, Affordability, and Decision Making
Efficient decisions about allocating health care budgets require assessment of the effects of health care interventions and the value for money they provide. Decision-making processes leading to funding decisions should be structured and evidence-based.
Real-World Evidence: Current Best Practice for Reimbursement Decision-Making
15 May 2023
In this report, we discuss best practices for RWE generation and the steps needed to enhance the assessment and use of quality RWE in reimbursement decisions.
How Restrictive are NICE ‘Optimised’ Decisions?
27 April 2023
NICE makes ‘optimised’ decisions to support use of medicines in smaller groups of patients. Between 2020 to 2022, 56% of optimised decisions recommended treatment for less than half of eligible patients.
Around The World in HTAs: Italy – What’s Next?
20 April 2023
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Claudio Jommi, Università del Piemonte Orientale Novara, and Martina Garau, OHE, take us to Italy.
Delivering the Triple Win: A Value-Based Approach to Pricing
20 April 2023
In this report, we investigate the theory and practice of value-based pricing in the pharmaceuticals industry, and provide recommendations for how implementation of value-based pricing can be enhanced to deliver the triple win of patient access; healthcare system sustainability; and innovation.
Cell & Gene Therapies: Can We Find Innovative Ways to Pay?
19 April 2023
OHE experts in Boston provided insights about innovative approaches to reimbursement for cell and gene therapies
Valuing Vaccines: The Economics of Vaccines & Immunisations
19 April 2023
Global experts discussed the value of equity in vaccine access worldwide and practitioners shared insights on economic evaluation in resource-constrained environments.
Caring about Carers: Improving Consideration of the Burden of Informal Caring in HTA
11 April 2023
Through a three-part webinar series, commissioned and funded by Roche, OHE has explored the burdens on informal carers when providing unpaid care for loved ones.
Around The World in HTAs: Spain – Are We There Yet?
15 March 2023
In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Laura Vallejo-Torres, University of Las Palmas de Gran Canaria, and Patricia Cubi-Molla, OHE, take us to Spain.
Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?
15 February 2023
Gene therapies pose fresh challenges for discounting practice by HTA agencies. In this blog, we discuss why discounting is important for gene therapies, using a potential gene therapy for X-Linked Retinitis Pigmentosa (XLRP) as an example.